PDF(Sci-hub)
Abstract：
Hyperprolactinemia is an underappreciated/unknown adverse effects of antipsychotics. The consequences of hyperprolactinemia compromise therapeutic adherence and can be serious. We present the consensus recommendations made by a group of experts regarding the management of antipsychotic-induced hyperprolactinemia. The current consensus was developed in 3 phases: 1, review of the scientific literature; 2, subsequent round table discussion to attempt to reach a consensus among the experts; and 3, review by all of the authors of the final conclusions until reaching a complete consensus. We include recommendations on the appropriate time to act after hyperprolactinemia detection and discuss the evidence on available options: decreasing the dose of the antipsychotic drug, switching antipsychotics, adding aripiprazole, adding dopaminergic agonists, and other type of treatment. The consensus also included recommendations for some specific populations such as patients with a first psychotic episode and the pediatric-youth population, bipolar disorder, personality disorders and the elderly population.
摘要：
高催乳素血症是抗精神病药的未被重视/未知的不良反应。高催乳素血症的后果会损害治疗依从性，并且可能很严重。我们提出了一组专家就抗精神病药引起的高催乳素血症的管理提出的共识建议。目前的共识分为三个阶段：1，科学文献审查；2，随后的圆桌会议讨论，试图在专家之间达成共识；3，所有作者对最终结论进行审查，直到达成完全共识。我们包括关于在检测到高催乳素血症后采取行动的适当时间的建议，并讨论可用选项的证据：减少抗精神病药物的剂量，转换抗精神病药，加入阿立哌唑，添加多巴胺能激动剂，和其他类型的治疗。共识还包括针对某些特定人群的建议，例如首次精神病发作的患者和儿童青年人群，双相情感障碍,人格障碍和老年人群。
